Ciprofloxacin prophylaxis in high risk neutropenic patients: Effects on outcomes, antimicrobial therapy and resistance

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Garnica, Marcia ^a   Nouér, Simone A ^a   Pellegrino, Flávia L P C ^a   Moreira, Beatriz M ^a   Maiolino, Angelo ^a   Nucci, Marcio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Febrile neutropenia; Neutropenia; Prophylaxis; Quinolone; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; CARBAPENEM; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; COAGULASE NEGATIVE STAPHYLOCOCCUS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INCIDENCE; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; CIPROFLOXACIN; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880939885     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-356     Document Type: Article

References (29)

1. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005, 353:977-987. 10.1056/NEJMoa044097, 16148283.
2. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005, 353:988-998. 10.1056/NEJMoa050078, 16148284.
3. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005, 142:979-995. 10.7326/0003-4819-142-12_Part_1-200506210-00008, 15968013.
4. Reuter S, Kern WV, Sigge A, Dohner H, Marre R, Kern P, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005, 40:1087-1093. 10.1086/428732, 15791505.
5. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007, 59:5-22.
6. Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006, 107:1743-1751. 10.1002/cncr.22205, 16977651.
7. Von BH, Sigge A, Bommer M, Kern WV, Marre R, Dohner H, et al. J Antimicrob Chemother 2006, 58:891-894. 10.1093/jac/dkl320, 16880172.
8. Kern WV, Steib-Bauert M, De WK, Reuter S, Bertz H, Frank U, et al. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002. J Antimicrob Chemother 2005, 55:57-60.
9. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von GA, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000, 30:473-478. 10.1086/313719, 10722430.
10. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2005, 49:2137-2139. 10.1128/AAC.49.5.2137-2139.2005, 1087677, 15855548.
11. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002, 46:196-202. 10.1128/AAC.46.1.196-202.2002, 126983, 11751134.
12. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001, 33:1288-1294. 10.1086/322667, 11565067.
13. Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009, 58:299-307. 10.1016/j.jinf.2009.02.002, 19272650.
14. Wener KM, Schechner V, Gold HS, Wright SB, Carmeli Y. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother 2010, 54:2010-2016. 10.1128/AAC.01131-09, 2863615, 20211888.
15. Oliveira AL, De SM, Carvalho-Dias VM, Ruiz MA, Silla L, Tanaka PY, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007, 39:775-781. 10.1038/sj.bmt.1705677, 17438585.
16. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012, 73:354-360. 10.1016/j.diagmicrobio.2012.04.007, 22656912.
17. From the Immunocompromised Host Society The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990, 161:397-401. 10.1093/infdis/161.3.397, 2179421, From the Immunocompromised Host Society.
18. Performance Standards for Antimicrobial Susceptibility Testing M100 S20 2010, USA: Clinical and Laboratory Standards Institute.
19. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988, 10:867-878. 10.1093/clinids/10.4.867, 3263690.
20. Renders N, Romling Y, Verbrugh H, Van BA. Comparative typing of Pseudomonas aeruginosa by random amplification of polymorphic DNA or pulsed-field gel electrophoresis of DNA macrorestriction fragments. J Clin Microbiol 1996, 34:3190-3195. 229481, 8940470.
21. Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 1991, 19:6823-6831. 10.1093/nar/19.24.6823, 329316, 1762913.
22. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996, 34:1129-1135. 228968, 8727889.
23. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:427-431. 10.1093/cid/ciq147, 21205990.
24. Wingard JR, Eldjerou L, Leather H. Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia. Curr Opin Hematol 2012, 19:21-26. 10.1097/MOH.0b013e32834da9bf, 22080847.
25. Eleutherakis-Papaiakovou E, Kostis E, Migkou M, Christoulas D, Terpos E, Gavriatopoulou M, et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol 2010, 85:863-867. 10.1002/ajh.21855, 20882526.
26. Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 2011, 15:e277-e281. 10.1016/j.ijid.2010.12.010, 21324723.
27. Craig M, Cumpston AD, Hobbs GR, Devetten MP, Sarwari AR, Ericson SG. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant 2007, 39:477-482. 10.1038/sj.bmt.1705591, 17322937.
28. Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Xercavins M, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 2003, 97:419-424. 10.1002/cncr.11044, 12518366.
29. Cremet L, Caroff N, Dauvergne S, Reynaud A, Lepelletier D, Corvec S. Prevalence of plasmid-mediated quinolone resistance determinants in ESBL Enterobacteriaceae clinical isolates over a 1-year period in a French hospital. Pathol Biol (Paris) 2011, 59:151-156.